R
Rhonda L. Bitting
Researcher at Wake Forest University
Publications - 58
Citations - 2309
Rhonda L. Bitting is an academic researcher from Wake Forest University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 18, co-authored 51 publications receiving 1937 citations. Previous affiliations of Rhonda L. Bitting include University of California, San Francisco & Duke University.
Papers
More filters
Journal ArticleDOI
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
Andrew J. Armstrong,Matthew S. Marengo,Sebastian Oltean,Sebastian Oltean,Gabor Kemeny,Rhonda L. Bitting,James D. Turnbull,Christina I. Herold,Christina I. Herold,Paul K. Marcom,Daniel J. George,Mariano A. Garcia-Blanco +11 more
TL;DR: The existence and high frequency of these C TCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.
Journal ArticleDOI
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
TL;DR: In this study of patients progressing after enzalutamide, treatment with abiraterone was associated with a modest response rate and brief duration of effect and may not preclude a response to abIRaterone.
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
TL;DR: The role of the PI3K/Akt/mTOR pathway in prostate cancer and the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer are reviewed.
Journal ArticleDOI
Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
TL;DR: This review has focused on advances in CTC isolation and organoid culture methods, and their potential applications in disease modeling and precision medicine.
Journal ArticleDOI
The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis.
TL;DR: Patients treated with combination chemotherapy had the greatest odds of remission and the lowest odds of death, and patients receiving immunosuppression had reduced odds of persistent hemophilia.